Completed PHASE1 INTERVENTIONAL 2-arm NCT06025552

Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects

A First-in-Human (FIH), Randomized, Double-Blind, Placebo-controlled, Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of TU7710 Following Single, Ascending, Intravenous, Dose Administration in Warfarin Anti-coagulated Healthy Male Subjects

Sponsor: TiumBio Co., Ltd.

Conditions Blood Coagulation Disorders Hemophilia B Hemophilia a

Interventions Normal saline TU7710

Updated 5 times since 2023 Last updated: Sep 25, 2024 Started: Aug 2, 2023 Primary completion: Aug 21, 2024 Completion: Aug 21, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Blood Coagulation Disorders and Hemophilia B, this trial is completed. The trial is conducted by TiumBio Co., Ltd. and has accumulated 5 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Oct 2024 — Sep 2025 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Aug 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TiumBio Co., Ltd.

Data source: TiumBio Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea